Opendata, web and dolomites

LeukoTheranostics SIGNED

Harnessing Targeted Nanotheranostics to Reprogram Activated Leukocytes in Inflammatory Bowel Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LeukoTheranostics project word cloud

Explore the words cloud of the LeukoTheranostics project. It provides you a very rough idea of what is the project "LeukoTheranostics" about.

micropet    urgent    ibd    unregulated    time    efficacy    diseases    million    pathogenesis    gut    community    conventional    therapeutic    fate    prevalence    approximately    interference    countries    dimensional    combined    unknown    15    onset    affinity    medical    first    patients    landscape    care    a4b7    implicated    persons    molecular    cells    rnai    integrin    nanoparticles    home    models    age    trojan    vivo    utilizing    40    etiology    gastrointestinal    peak    theranostic    bowel    uc    colitis    horse    expressed    activated    strategy    conformation    platform    chronic    tsnps    trials    tract    clinical    health    annual    rodent    reprogram    safety    profiles    prepare    indirect    meet    europeans    modalities    disease    modality    burden    strategies    near    ct    primary    small    immune    cd    rna    therapeutics    generating    leukocytes    refractory    inflammation    imposes    crohn    3b    combination    imaging    lay    ulcerative    foundation    treatments    group    decade    inflammatory   

Project "LeukoTheranostics" data sheet

The following table provides information about the project.

Coordinator
TEL AVIV UNIVERSITY 

Organization address
address: RAMAT AVIV
city: TEL AVIV
postcode: 69978
website: http://www.tau.ac.il/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www3.tau.ac.il/danpeer/index.php/eu-project
 Total cost 2˙703˙125 €
 EC max contribution 2˙703˙125 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-CoG
 Funding Scheme ERC-COG
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TEL AVIV UNIVERSITY IL (TEL AVIV) coordinator 2˙527˙608.00
2    CHILDREN'S HOSPITAL CORPORATION US (BOSTON) participant 175˙517.00

Map

 Project objective

'Inflammatory bowel diseases (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn’s disease (CD) and Ulcerative Colitis (UC) that can impact both the large and small bowel. IBD affects approximately 3.7 million Europeans and its peak onset is in persons of 15 to 30 years of age. IBD imposes a significant burden on Europe with over €3B in annual health care costs and over €3B in indirect cost. The prevalence of IBD is expected to increase by more than 40% over the next decade in many European countries. Therefore, to meet the needs of IBD patients in the European community, we must prepare for the evolving landscape of IBD care in the near future. Although its etiology remains unknown, unregulated immune cells are implicated in the pathogenesis of IBD. As many IBD patients are refractory to conventional medical treatments, there is an urgent need to develop novel therapeutic modalities in combination with real-time imaging in order to manage the disease. I will achieve this goal by generating a 'Trojan horse' strategy of targeting activated leukocytes that home to the gut in IBD rodent models and reprogram their fate using RNA interference (RNAi) combined with molecular imaging. The primary objective of this proposal is to reprogram in vivo activated leukocytes involved in gut inflammation using advanced RNAi-based therapeutics combined with molecular imaging strategies as the first theranostic modality utilizing leukocytes. The following specific aims include: (i) To develop and characterize unique integrin-targeted nanoparticles (I-tsNPs) targeting a high-affinity (HA) conformation of a4b7 integrin expressed on gut leukocytes; (ii) To study I-tsNPs 3-dimensional (3-D) delivery in colitis models using microPET/CT imaging; (iii) To investigate efficacy and safety profiles using the HA I-tsNPs platform for IBD therapeutics and disease management that will lay the foundation for future clinical trials. '

 Publications

year authors and title journal last update
List of publications.
2018 Ranit Kedmi, Nuphar Veiga, Srinivas Ramishetti, Meir Goldsmith, Daniel Rosenblum, Niels Dammes, Inbal Hazan-Halevy, Limor Nahary, Shani Leviatan-Ben-Arye, Michael Harlev, Mark Behlke, Itai Benhar, Judy Lieberman, Dan Peer
A modular platform for targeted RNAi therapeutics
published pages: 214-219, ISSN: 1748-3387, DOI: 10.1038/s41565-017-0043-5
Nature Nanotechnology 13/3 2020-02-21
2018 Daniel Rosenblum, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Dan Peer
Progress and challenges towards targeted delivery of cancer therapeutics
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-03705-y
Nature Communications 9/1 2020-02-21
2018 Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti, Dan Peer
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-06936-1
Nature Communications 9/1 2020-02-21
2017 Shoshy Mizrahy, Inbal Hazan-Halevy, Niels Dammes, Dalit Landesman-Milo, Dan Peer
Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes
published pages: , ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.03.001
Molecular Therapy 2020-02-21
2016 Inbal Hazan-Halevy, Dalit Landesman-Milo, Daniel Rosenblum, Shoshy Mizrahy, Brandon D. Ng, Dan Peer
Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines
published pages: 149-156, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2016.07.052
Journal of Controlled Release 244 2020-02-21

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKOTHERANOSTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEUKOTHERANOSTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More